---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-22-000034"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2022-08-23T23:59:59+00:00"
generated_at: "2026-06-23T22:00:24.208691+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q1 FY2023 revenue $7.37B (-4% organic) beats guidance; non-GAAP EPS $1.13 in line

## Summary
- GAAP diluted EPS $0.70 (+25% YoY); non-GAAP diluted EPS $1.13 (-17% YoY), in line with expectations.
- Revenue $7.371B, down 8% as reported (-4% organic), ahead of guidance; organic excludes $351M FX and $20M Intersect ENT.
- Cardiovascular -1% organic, Medical Surgical -9% organic, Neuroscience -2% organic, Diabetes flat organic.
- FY2023 guidance reiterated: organic revenue growth 4-5%, non-GAAP EPS $5.53-$5.65; FX headwind raised to $1.4-$1.5B.
- Strength in Pacing (mid-teens Micra), Core Spine in US, CGM in Europe; ventilators declined low-fifties.

## SEC filing metadata
- accession: 0001613103-22-000034
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2022-08-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000034/0001613103-22-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000034/mdt-20220823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-22-000034
- JSON: https://secwatch.observer/filing/0001613103-22-000034.json
- Plain text: https://secwatch.observer/filing/0001613103-22-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.